Results 51 to 60 of about 113,281 (294)

Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects

Molecular Metabolism, 2017
Objective: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) possess multiple bioactive isoforms that are rendered non-insulinotropic by the enzyme dipeptidyl peptidase-4 (DPP-4).
Tsuyoshi Yanagimachi, Yukihiro Fujita, Yasutaka Takeda, Jun Honjo, Hidemitsu Sakagami, Hiroya Kitsunai, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Timothy J. Kieffer, Masakazu Haneda   +10 more
doaj   +1 more source

Asymmetric Synthesis of Highly Functionalized Tetrahydropyran DPP‑4 Inhibitor

, 2016
A practical synthesis of a highly functionalized tetrahydropyran DPP-4 inhibitor is described. The asymmetric synthesis relies on three back-to-back Ru-catalyzed reactions.
Yoshinori Kohmura (1734763), Mahbub Alam (734001), Jeremy Scott (1734766), Michael J. Zacuto (1734769), Feng Xu (89016), David Tschaen (1734760), Andrew Gibb (667403), Jon Rosen (1734772)   +7 more
core   +1 more source

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure [PDF]

, 2011
Background Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half ...
Rudolf A de Boer, Maxi Meissner, van Gilst Wiek H, Wiek H van Gilst, de Boer, Rudolf A., Yin Meimei, de Boer Rudolf A, Sillje, Herman H. W., van Gilst, Wiek H., Meimei Yin, Meissner Maxi, Silljé Herman HW, Yin, Meimei, Herman HW Silljé, Meissner, Maxi   +14 more
core   +1 more source

SuFEx‐Enabled Reprogramming of Flavonoids for Selective α‐Glucosidase Covalent Inhibition

Advanced Science, EarlyView.
Selective inhibition of intestinal α‐glucosidase remains limited by poor enzyme specificity and off‐target metabolic effects. Here, SuFEx click chemistry is used to reprogram natural flavonoids into covalent inhibitors with enhanced α‐glucosidase selectivity and controlled reactivity. This strategy enables effective regulation of carbohydrate digestion
Fengyu Guo, Liwei Zhang, Minlong Wang, Yanjin Du, Tianyu Zhang, Hao Chen, Jiazeng Sun, Yang Yu, Zude He, Jie An, Xiaoxu Zhang, Weilin Lin, Fazheng Ren, Pengjie Wang, Ping Liu   +14 more
wiley   +1 more source

Biomimetic Hydrogel System Targeting S100A8 Centered Neuroimmune Crosstalk and Hypoxia Induced Neuronal Injury

Advanced Science, EarlyView.
A biomimetic hydrogel (HPC@Gel) was developed for traumatic brain injury repair by combining oxygen‐carrying hemoglobin nanoparticles and anti‐inflammatory carbon quantum dots within a brain‐like matrix. The system alleviated hypoxia, reduced harmful neuroimmune signaling, protected neurons, supported neural regeneration, and improved neurological and ...
Peng Liu, Xiaoyang Wu, Xiaoyin Liu, Yuyan Wang, Shichao Jiang, Kai Wu, Gaowei Li, Jie Ding, Chengheng Wu, Dan Wei, Jing Sun, Hongsong Fan, Liangxue Zhou   +12 more
wiley   +1 more source

Study on Anti-inflammatory and Anti-oxidative Stress Mechanism of Sitagliptin: a Dipeptidyl Peptidase-4 Inhibitor [PDF]

Zhongguo quanke yixue
The prevalence rate of type 2 diabetes is increasing year by year. It is known that oxidative stress and inflammation can participate in the occurrence and development of diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors can enhance the incretin effect
ZHU Jing, XIE Ji, HU Xiaoxia
doaj   +1 more source

Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report

American Journal of Ophthalmology Case Reports, 2023
Purpose: To report a rare Ocular Cicatricial Pemphigoid (OCP) case in a patient taking a Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor), a medication used for the management of type 2 diabetes, for at least six years. Observations: A 64-year-old male
Akifumi Matsumoto, Hideki Fukuoka, Akiko Yoneda, Norihiko Yokoi, Chie Sotozono   +4 more
doaj   +1 more source

Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes. [PDF]

, 2012
Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the
Rauch, Thomas, Heise, Tim, Holst, Jens Juul, Graefe-Mody, U, Dugi, Klaus A, Rauch, T, Ring, A, Dugi, KA, Graefe-Mody, Ulrike, Deacon, Carolyn F., Heise, T, Deacon, Carolyn F, Ring, Arne, Woerle, Hans-Juergen, Woerle, H-J   +14 more
core   +1 more source

eEF1G Orchestrates Translation to Ensure Meiotic Progression in Transcriptionally Quiescent Spermatocytes

Advanced Science, EarlyView.
eEF1G supports translation elongation of meiotic mRNAs in transcriptionally quiescent leptotene and zygotene spermatocytes. Its depletion in germ cells causes meiotic arrest at the zygotene stage, with defective homologous synapsis and unstable recombination intermediates.
Jianze Xu, Yuwei Hu, Xukun Lu, Yuling Cai, Tongtong Li, Ming Gao, Jinlong Ma, Yuan Gao, Shangming Liu, Zi‐Jiang Chen, Jing Meng, Hongbin Liu, Xiaohua Jiang   +12 more
wiley   +1 more source

DPP-4 inhibition protects human umbilical vein endothelial cells from hypoxia-induced vascular barrier impairment

Journal of Pharmacological Sciences, 2017
Dipeptidyl peptidase-4 (DPP-4) inhibitors are relatively new class of anti-diabetic drugs. Some protective effects of DPP-4 on cardiovascular disease have been described independently from glucose-lowering effect.
Naoko Hashimoto, Kento Ikuma, Yui Konno, Masanori Hirose, Hiroyuki Tadokoro, Hiroshi Hasegawa, Yoshio Kobayashi, Hiroyuki Takano   +7 more
doaj   +1 more source